Document is current
Any future updates will be listed below
-
Authors
Bewersdorf, Jan Philipp https://orcid.org/0000-0003-3352-0902
Giri, Smith
Wang, Rong
Podoltsev, Nikolai https://orcid.org/0000-0002-3657-778X
Williams, Robert T.
Tallman, Martin S.
Rampal, Raajit K.
Zeidan, Amer M.
Stahl, Maximilian https://orcid.org/0000-0002-1299-5901
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA008748, P30 CA016359)
U.S. Department of Health & Human Services | National Institutes of Health
Funders listed above apply for the entire manuscript
- License Information
-
More Information
Article History
Received: 24 March 2020
Revised: 28 July 2020
Accepted: 6 August 2020
First Online: 1 September 2020
Compliance with ethical standards
:
: NAP consulted for and received honoraria from Alexion, Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol-Myers Squib and CTI biopharma. NAP received research funding (all to the institution) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals and Kartos Therapeutics. MST has received research funding from Abbvie, Cellerant, Orsenix, ADC Therapeutics, and Biosight. RKR has received consulting fees from: Constellation, Incyte, Celgene, Promedior, CTI, Jazz Pharmaceuticals, Blueprint, Stemline, and research funding from Incyte, Constellation, Stemline. MST has received honoraria for MST has received research funding from Abbvie, Cellerant, Orsenix, ADC Therapeutics, and Biosight. MST has received honoraria for advisory board membership from Abbvie, BioLineRx, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, and Jazz Pharma. MST received patents and royalties from UpToDate. AMZ received research funding (institutional) from Celgene, Acceleron, Abbvie, Novartis, Otsuka, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, and ADC Therapeutics. AMZ had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Jazz, Ariad, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Seattle Genetics, BeyondSpring, Trovagene, Ionis, Epizyme, Amgen, Tyme, Janssen, and Takeda. AMZ received travel support for meetings from Pfizer, Novartis, and Trovagene. None of these relationships were related to the development of this manuscript. All other authors report no relevant disclosures/competing interests.
